Internal medicine journal
-
Internal medicine journal · Oct 2022
Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late-stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group.